This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
AbbVie's HCV Combo Favorable in Japanese Phase III Study
by Zacks Equity Research
AbbVie Inc. (ABBV) announced positive top-line data from a phase III study on its pan-genotypic ribavirin (RBV)-free regimen of glecaprevir/pibrentasvir (G/P) in Japanese patients.
Ionis, Novartis Ink Deal to Focus on Cardiovascular Treatments
by Zacks Equity Research
Ionis (IONS) entered into a collaboration agreement with Novartis (NVS) for the development and commercialization of AKCEA-APO(a)-L and AKCEA-APOCIII-L.
Vertex Pharma Issues Disappointing 2017 Orkambi Outlook
by Zacks Equity Research
Vertex Pharmaceuticals Incorporated (VRTX) announced preliminary financial results for 2016 and issued a financial outlook for 2017 on Jan 8, ahead of a Jan 9 presentation at the JP Morgan healthcare conference in San Francisco.
Genocea Stock Up on Positive Genital Herpes Infections Data
by Zacks Equity Research
Genocea Biosciences, Inc. (GNCA) announced encouraging six-month data from a planned interim analysis of its ongoing placebo-controlled phase IIb study on GEN-003 for the treatment of genital herpes infections.
Biogen Licenses Amunix's XTEN Technology for Factor IX Drug
by Zacks Equity Research
Biogen Inc. (BIIB) exercised its option to enter into an exclusive, global license agreement with Amunix Operating Inc. to incorporate the latter's proprietary XTEN half-life extension technology in developing a recombinant Factor IX candidate.
Halozyme (HALO) Up on Positive Phase II Data on PEGPH20
by Zacks Equity Research
Halozyme (HALO) announced top-line data from the combined analysis from its phase II HALO 202 study on PEGPH20.
Ultragenyx's (RARE) KRN23 Accepted for Review in the EU
by Zacks Equity Research
Ultragenyx (RARE) announced that EMA has accepted to review its MAA for KRN23 for the treatment of X-linked hypophosphatemia.
Argos Therapeutics (ARGS) Looks Good: Stock Rises by 5%
by Zacks Equity Research
Argos Therapeutics, Inc.(ARGS) was a big mover last session, as the company saw its shares rise 5% on the day.
Arena, Eisai Modify Marketing & Supply Agreement for Belviq
by Zacks Equity Research
Arena Pharmaceuticals, Inc. (ARNA) announced that it has amended the marketing and supply agreement with Eisai Co., Ltd. (ESALY) for Belviq.
Spark Therapeutics Gets $15M Milestone Payment from Pfizer
by Zacks Equity Research
Spark Therapeutics (ONCE) received a $15 million milestone payment from partner Pfizer Inc. (PFE) for achieving a pre-specified safety and efficacy profile in the phase I/II study on SPK-9001, which is being evaluated for the treatment of hemophilia B.
Alexion (ALXN) Stock Up on 10Q Filing; 2016 View Retained
by Zacks Equity Research
Alexion (ALXN) has finally announced the filing of its Form 10-Q with the SEC for the period ended Sep 30, 2016 and retained its outlook for 2016.
Clovis Declares Pricing of Upsized Offering of Common Stock
by Zacks Equity Research
Clovis Oncology, Inc. (CLVS) announced the pricing of its underwritten public offering of common stock worth $5 million.
Alexion (ALXN): Will the Stock Continue to Suffer in 2017?
by Zacks Equity Research
Given the delay in filing the 10-Q, departure of key executives, pipeline setbacks and the ongoing drug pricing issues, Alexion seems to be heading toward difficult times in 2017.
Is Vertex Pharma (VRTX) Poised for a Turnaround in 2017?
by Zacks Equity Research
Vertex Pharmaceuticals, Inc.'s (VRTX) main therapeutic area of focus is cystic fibrosis (CF). Presently, the company markets two medicines for the disease, Kalydeco and Orkambi.
Corbus Concludes Phase II study of Cystic Fibrosis Candidate
by Zacks Equity Research
Corbus Pharmaceuticals Holdings, Inc. (CRBP), recently announced that it has concluded Phase II trial evaluating pipeline candidate, JBT-101 (resunab), for the treatment of cystic fibrosis (CF).
Apricus Launches Vitaros in Lebanon for Erectile Dysfunction
by Zacks Equity Research
Apricus Biosciences, Inc. (APRI) announced that its topical cream, Vitaros for the treatment of erectile dysfunction (ED) has been launched in Lebanon by partner Elis Pharmaceuticals Ltd.
Neothetics (NEOT) Begins Phase II Study on Lead Candidate
by Zacks Equity Research
Neothetics, Inc. (NEOT) announced that it has commenced a phase II proof-of-concept study, LIPO-202-CL-31, on its lead candidate, LIPO-202, for the reduction of submental subcutaneous fat.
Horizon's Rare Disease Drug Quinsair Launched in Canada
by Zacks Equity Research
Horizon Pharma plc (HZNP) announced the availability of Quinsair (levofloxacin inhalation solution) in Canada for the management of chronic pulmonary infections.
Celgene's Otezla Gains Positive Recommendation from NICE
by Zacks Equity Research
Celgene Corporation (CELG) announced that the National Institute for Health and Care Excellence (NICE) has issued a final appraisal determination, recommending the use of its oral phosphodiesterase 4, Otezla.
ACADIA Phase II Alzheimer's Drug Hits Primary Endpoint
by Zacks Equity Research
ACADIA Pharmaceuticals Inc. (ACAD) announced that a phase II exploratory study (-019 Study) evaluating pimavanserin for the treatment of Alzheimer's disease psychosis (AD Psychosis) met the primary endpoint.
AbbVie (ABBV) Submits NDA for Next-Gen HCV Combo in US
by Zacks Equity Research
AbbVie Inc. (ABBV) announced that it has submitted a New Drug Application (NDA) to the FDA for its pan-genotypic regimen of glecaprevir/pibrentasvir (G/P).
Roche Presents Positive Follicular Lymphoma Data on Gazvya
by Zacks Equity Research
Roche Holding AG (RHHBY) announced encouraging data from the pivotal phase III study, GALLIUM.
Pfizer Leukemia Drug Meets Primary Endpoint in Phase III
by Zacks Equity Research
Pfizer Inc. (PFE) and partner Avillion LLP announced that a phase III study (BFORE) evaluating its marketed drug Bosulif in the first-line setting met the primary endpoint
GW Pharma (GWPH) Posts Narrower-than-Expected Q4 Loss
by Zacks Equity Research
GW Pharmaceuticals (GWPH) reported a narrower-than-expected loss of 89 cents per share in the fourth quarter of fiscal 2016 (ended Sep 30, 2016).
Alexion Presents Data from Ultra-Rare Blood Disorder Study
by Zacks Equity Research
Alexion Pharmaceuticals (ALXN) presented new data from a dose-escalation study on ALXN1210 in patients with paroxysmal nocturnal hemoglobinuria at ASH.